Nymox Pharmaceutical Corp (NASDAQ:NYMX) saw a large drop in short interest in July. As of July 15th, there was short interest totalling 1,405,000 shares, a drop of 20.3% from the June 15th total of 1,763,800 shares. Based on an average daily trading volume, of 142,900 shares, the short-interest ratio is currently 9.8 days. Approximately 3.7% of the company’s stock are sold short.

NYMX stock traded up $0.02 on Friday, reaching $1.72. 36,398 shares of the company traded hands, compared to its average volume of 268,696. Nymox Pharmaceutical has a one year low of $1.25 and a one year high of $3.33. The company has a quick ratio of 8.01, a current ratio of 8.04 and a debt-to-equity ratio of 0.03. The firm’s fifty day simple moving average is $1.61.

Nymox Pharmaceutical (NASDAQ:NYMX) last posted its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter. Nymox Pharmaceutical had a negative net margin of 6,101.69% and a negative return on equity of 175.82%. The company had revenue of $0.03 million for the quarter.

A number of institutional investors and hedge funds have recently modified their holdings of NYMX. Brown Advisory Inc. purchased a new stake in Nymox Pharmaceutical during the 4th quarter valued at $34,000. Rhumbline Advisers boosted its stake in Nymox Pharmaceutical by 44.9% during the 4th quarter. Rhumbline Advisers now owns 42,560 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 13,180 shares during the last quarter. Willow Creek Wealth Management Inc. boosted its stake in Nymox Pharmaceutical by 94.3% during the 1st quarter. Willow Creek Wealth Management Inc. now owns 34,124 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 16,562 shares during the last quarter. Geode Capital Management LLC boosted its stake in Nymox Pharmaceutical by 10.8% during the 4th quarter. Geode Capital Management LLC now owns 134,021 shares of the biopharmaceutical company’s stock valued at $175,000 after purchasing an additional 13,103 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in Nymox Pharmaceutical by 130.1% during the 4th quarter. Bank of America Corp DE now owns 148,443 shares of the biopharmaceutical company’s stock valued at $195,000 after purchasing an additional 83,925 shares during the last quarter. Institutional investors and hedge funds own 5.66% of the company’s stock.

Nymox Pharmaceutical Company Profile

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease.

See Also: The mechanics of the bid-ask spread in trading

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.